This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Sarepta, Acadia, Vical and a Hep C Preview

@themicrokid tweets, "Be nice if $SRPT gave us some insight as to when they might share some 62-week data that was taken a couple weeks ago."

Agreed. I rank more data from the eteplirsen phase IIb study as the second-most significant catalyst looming for Sarepta. Eteplirsen doubters probably rank this first, understandably.

On the call Wednesday night, Sarepta said additional assessments of DMD patients in the eteplirsen trial are being conducted at 62 weeks and 74 weeks, but the company didn't offer a timeline for when these data would be released. Just like what we saw with the 48-week data in October, stabilization of disease progression (or better yet) improvement would make the case for early approval even stronger -- if not a slam dunk.

@Hachidi asks, "How come $SRPT tapping ATM before data is good, but for $ACAD is a red flag?"

I was rebuked by a bunch of readers for my column raising a red flag on Acadia Pharmaceuticals' (ACAD - Get Report) decision to sell stock through its At-the-Market (ATM) equity facility ahead of announcing results from the pimavanserin phase III study. It's true, Sarepta also sold stock through an ATM agreement prior to releasing eteplirsen data, and yes, I didn't raise a ruckus about it, so why is Acadia different?

Point taken and appreciated. In my defense, I'll say that among institutional investors there was ample discussion -- and some degree of consternation -- about Sarepta's ATM and whether management would use it before the eteplirsen data came out. I was also more confident in eteplirsen than I am with pimavanserin currently. I have my doubts about the upcoming Parkinson's psychosis trial based on the previous trial data but I'm also more than happy to be persuaded otherwise if the new results come back positive.

The opacity of ATMs is what I primarily object to. Shareholders have no way of knowing if or when management is selling stock until well after the fact. I prefer traditional stock offerings for their relative transparency, even though I understand that ATMs carry certain fiscal advantages.

While on the subject, Vical (VICL - Get Report) entered into a $50 million ATM facility on Wednesday. The disclosure was made in an SEC filing yet Vical said nothing about the ATM in its third-quarter earnings release or during the conference call held the same day.

No transparency! You see what I mean with these ATMs?

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ABT $49.03 -0.63%
ACAD $40.55 0.82%
GILD $111.71 0.44%
SRPT $26.22 8.08%
VICL $0.93 4.04%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs